Chromosomal Deletion Linked to Syndromic Diabetes and Hypogonadism in a 12-Year-Old Boy

October 4, 2026 2 Min Read

Overview of the Case

A recent clinical report highlights a 12-year-old boy presenting with a complex syndrome involving diabetes and hypogonadism, linked to a chromosomal deletion on 12q24.31-32. This deletion includes several genes known to influence metabolic, developmental, and endocrine functions.

Genetic Findings and Associated Conditions

The boy was found to have an 8.6-megabase deletion encompassing the HNF1A, DHX37, and SETD1B genes. Each of these genes has been previously associated with distinct disorders:

HNF1A: Known to cause maturity-onset diabetes of the young (MODY), a form of diabetes characterized by early onset and impaired insulin production.
DHX37: Variants in this gene have been linked to 46,XY disorders of sex development, suggesting a role in gonadal function.
SETD1B: Associated with syndromic neurodevelopmental disorders, including intellectual disability and autism spectrum disorder.

Clinical Presentation and Diagnosis

The boy was born small for gestational age and exhibited multiple developmental challenges including seizures, autism spectrum disorder, hearing loss, short stature, and intellectual disability. At five years old, genetic analysis using array-based comparative genomic hybridization identified the chromosomal deletion.

By age 12, he developed diabetes characterized by the absence of islet autoantibodies, indicating a non-autoimmune form of diabetes consistent with HNF1A involvement.

Management Considerations

Due to the boy’s intellectual disability, managing hypoglycemia through self-care was difficult. Therefore, clinicians opted for a treatment regimen including nateglinide and insulin therapy, rather than sulfonylurea drugs, to better suit his needs.

Additionally, the deletion’s impact on DHX37 was considered a likely cause of his hypergonadotropic hypogonadism, a condition where the gonads produce insufficient sex hormones despite elevated stimulating hormones.

Implications for Families and Clinicians

This case underscores the importance of personalized diabetes management strategies for children with intellectual disabilities and complex genetic backgrounds. It also highlights the potential for associated endocrine disorders such as hypogonadism when genes like DHX37 are affected.

Limitations and Future Directions

While the deletion clearly involves genes linked to the boy’s clinical features, the exact mechanisms remain to be fully elucidated. Further research is needed to better understand the interplay between these genes and the resulting phenotypes.

For more detailed information, the original study can be accessed here.